Grand River Aseptic Manufacturing

Grand River Aseptic Manufacturing specializes in contract development and manufacturing services, focusing on aseptic filling for pharmaceutical products, including prefilled syringes and cartridges, ensuring high standards of sterility and reliability in drug delivery. Founded in 2011 in Grand Rapids, US, Grand River Aseptic Manufacturing provides aseptic filling services, specifically for prefilled syringes and cartridges. The company was acquired by Arlington Capital Partners from BrightPath Capital in November 2017, enhancing its operational capabilities. Jerry Callahan, the founder, has a history of establishing successful ventures in the pharmaceutical manufacturing sector.

As of November 2017, the company has raised a total of USD 7. 58 mn across its Series C funding round, reflecting its growth trajectory with a current company valuation of USD 23. 44 mn. Grand River Aseptic Manufacturing (GRAM) specializes in providing contract development and manufacturing services, primarily focusing on aseptic filling for prefilled syringes (PFS) and cartridges.

Their core offerings encompass a state-of-the-art fill-finish process for liquid and lyophilized vials, as well as prefilled syringes and cartridges, designed to meet the rigorous demands of drug delivery device companies. GRAM's services are positioned to address critical needs in the pharmaceutical industry, including ensuring sterility, enhancing product stability, and facilitating patient convenience in drug administration. With a strong emphasis on quality and regulatory compliance, their client base includes pharmaceutical and biotechnology companies seeking reliable manufacturing partners to streamline their supply chains and enhance product delivery across North America and Europe. The revenue model of Grand River Aseptic Manufacturing is built on B2B transactions involving partnerships with pharmaceutical firms and drug delivery device manufacturers.

The company engages in contract agreements for the aseptic filling and finishing of products, with clients typically providing their formulations for processing. These transactions often entail long-term contracts, where clients pay for services based on batch production or volume, allowing for scalable production aligned with demand. GRAM’s flagship services include aseptic filling of prefilled syringes and cartridges, which are crucial for various therapeutic applications. The pricing structure is determined by the specific requirements of the manufacturing process, including batch size, complexity of the formulation, and regulatory considerations, ensuring tailored solutions for each client engagement.

Grand River Aseptic Manufacturing plans to enhance its service offerings with the introduction of new products and technologies aimed at improving aseptic filling processes, although specific release dates have not been specified. The company is strategically targeting expansions into European markets to leverage the growing demand for sterile drug delivery systems, with efforts expected to ramp up post-2023. Funding from the Series C round will be utilized to support these expansion initiatives and infrastructure improvements to meet increased client demands.